Galle, Eva <br/><br/>
DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer.  [electronic resource] 

 -  Clinical epigenetics  02 2020 
 - 27 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1868-7083 
<br/><br/><label>Standard No.: </label>10.1186/s13148-020-0821-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Azacitidine--therapeutic use<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Line, Tumor--drug effects<br/>Circulating Tumor DNA--genetics<br/>DNA Methylation--genetics<br/>Drug Resistance, Neoplasm--genetics<br/>Enzyme Inhibitors--therapeutic use<br/>Epigenesis, Genetic<br/>Epithelial-Mesenchymal Transition--genetics<br/>Gene Expression Regulation, Neoplastic--genetics<br/>Humans<br/>Liver Neoplasms--pathology<br/>MicroRNAs--genetics<br/>Protein Kinase Inhibitors--therapeutic use<br/>Sorafenib--therapeutic use